Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
Researchers at St. Jude Children's Research Hospital have discovered that a protein critical to a process called liquid-liquid phase separation within the cell undergoes internal changes in conformation that are key to its function.
A research team led by a biochemist at the University of California, Riverside has solved the crystal structure for an enzyme that plays a key role in DNA methylation, the process by which methyl groups are added to the DNA molecule.
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer.
The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation.
AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LYNPARZA (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
Patients with an aggressive form of leukemia, currently ineligible for any type of targeted therapy, may in fact benefit from some of these new drugs, according to new research by Queen Mary University of London.
Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna® (nilotinib) US product label.
In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the U.S. Food and Drug Administration found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in this age group, according to research being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.
Researchers from Instituto de Medicina Molecular João Lobo Antunes have found a mechanism through which certain types of leukemia resist chemotherapy, thus revealing novel molecular targets that may be used to improve the efficiency of this type of treatment.
Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers at The University of Texas MD Anderson Cancer Center.
University of North Carolina Lineberger Comprehensive Cancer Center researchers report that pairing an immunotherapy drug with chemotherapy proved beneficial for some patients with acute myeloid leukemia whose disease did not respond to standard treatment or had relapsed.
A clinical trial using genetic testing to match acute myeloid leukemia (AML) patients with new therapies is now open at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine unanimously approved yesterday two grants worth a total of almost $8 million to University of California San Diego School of Medicine researchers investigating novel stem cell-based treatments for acute myeloid leukemia or AML.
A study has found an unexpected new drug target for acute myeloid leukemia (AML) that could open new avenues to develop effective treatments against this potentially lethal disease.
Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.
Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse.
Killing cancer cells indirectly by powering up fat cells in the bone marrow could help acute myeloid leukemia patients, according to a new study from McMaster University.
Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative strategies to identify and test new drugs quicker and more efficiently.
Researchers have discovered a compound that can trigger cancer cells to self-destruct, without causing any damage to healthy cells.
Scientists at Albert Einstein College of Medicine have discovered the first compound that directly makes cancer cells commit suicide while sparing healthy cells.